Company profile: Visikol
1.1 - Company Overview
Company description
- Provider of CRO services focused on digital pathology, 3D tissue imaging, and 3D cell culture assays/models. Delivers end-to-end 2D/3D in vitro models, tissue clearing (Visikol HISTO) and confocal microscopy, high content screening, bio-imaging, bioinformatics and image analysis, plus custom drug discovery solutions and 21 CFR Part 11 compliant digital pathology software.
Products and services
- Digital Pathology: Delivers slide scanning and data storage, plus custom development of 21 CFR Part 11-compliant digital pathology software to build tailored digital pathology systems
- Tissue Imaging and Analysis Services: Architects labeling, processing, and imaging workflows to enable 3D whole-mount tissue characterization with Visikol HISTO clearing and confocal microscopy for detailed visualization
- 3D Cell Culture Assay Services: Produces end-to-end 3D cell culture assays with a broad portfolio of characterization endpoints, including plate reading and high-content confocal microscopy.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Visikol
Aethon
HQ: United States
Website
- Description: Provider of automated hospital delivery and asset management solutions, including TUG®, an automated robotic delivery system transporting scheduled and on-demand deliveries across ancillary, support and patient care units. Offers autonomous mobile robots for material handling in hospitals, manufacturing and hotels, with secured delivery, cart handling, and payloads up to 1,400 lb.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aethon company profile →
CN Bio
HQ: United Kingdom
Website
- Description: Provider of human organ-on-a-chip platforms and services for drug discovery and disease research, including PhysioMimix OOC single- and multi-organ systems, PhysioMimix HT for higher-throughput R&D, contract research services, and liver and lung assays covering NASH, HBV, and COVID-19 for long-term culture, infection modeling, drug efficacy, safety testing, and immune response studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CN Bio company profile →
M2P Labs
HQ: Germany
Website
- Description: Provider of microbioreactor and biochemical engineering solutions, including the BioLector high-throughput microbioreactor for microliter-scale fermentation with online monitoring (biomass, pH, dissolved oxygen, fluorescence); the RoboLector automated cultivation platform with liquid handling; and the FlowerPlate microtiter plate for enhanced oxygen transfer, plus technical/application support, demos, installation, and maintenance contracts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full M2P Labs company profile →
NeuroVigil
HQ: United States
Website
- Description: Provider of non-invasive brain monitors for analyzing neurological conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeuroVigil company profile →
CMA Microdialysis
HQ: Sweden
Website
- Description: Provider of specialized tools for biological research in preclinical settings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CMA Microdialysis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Visikol
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Visikol
2.2 - Growth funds investing in similar companies to Visikol
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Visikol
4.2 - Public trading comparable groups for Visikol
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →